重组人粒细胞刺激因子用于乳腺癌化疗后辅助治疗专项点评

目的 了解乳腺癌化疗后辅助治疗药物重组人粒细胞刺激因子的使用情况，促进肿瘤化疗患者合理使用此类药物。方法 汇总2016年厦门市妇幼保健院全部乳腺癌化疗病历，抽取150份，建立点评依据，对重组人粒细胞刺激因子用药的适应证、给药时机、用法用量等进行点评。结果 厦门市妇幼保健院重组人粒细胞刺激因子用于乳腺癌化疗后辅助治疗，在预防使用方面主要为给药时机不合理，占总抽查病历的20.22%；而治疗使用方面主要体现为适应证不合理，占总抽查病历的26.23%。结论 临床药师应加强此类药物的监控与评价，寻求、创造更好的循证医学证据，促进临床合理用药。

Special Evaluation of Recombinant Human Granulocyte Colony-stimulating Factor for the Adjuvant Treatment after Chemotherapy in Breast Cancer

OBJECTIVE To analysis the utilization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in adjuvant treatment after chemotherapy in breast cancer, in order to improve the rationality of these drugs in patients with tumor undergoing chemotherapy. METHODS To select 150 cases from all the medical record in Xiamen Maternity and Child Health Care Hospital in 2016 of chemotherapy in breast cancer. Establishing evaluation criterion to analysis the indication, appropriate time, usage and dosage of rhG-CSF, et al. RESULTS rhG-CSF was used for adjuvant treatment after chemotherapy in breast cancer in Xiamen Maternity and Child Health Care Hospital. Unresonable prophylactic use was mainly in inappropriate time (accounting for 20.22%) while unreasonable therapeutic use was mainly in indication (accounting for 26.23%). CONCLUSION Monitoring and assessment of these drugs shall be enhanced while searching for the better evidence in order to promote rational drug use.